Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. TARA.O
stocks logo

TARA.O

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.352
-18.02%
--
--
-0.362
+25%
--
--
-0.357
+2.14%
Estimates Revision
The market is revising No Change the revenue expectations for Protara Therapeutics, Inc. (TARA) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 116.72%.
EPS Estimates for FY2025
Revise Downward
down Image
-8.95%
In Past 3 Month
Stock Price
Go Up
up Image
+116.72%
In Past 3 Month
Wall Street analysts forecast TARA.O stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TARA.O is 23.33 USD with a low forecast of 21.00 USD and a high forecast of 26.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast TARA.O stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TARA.O is 23.33 USD with a low forecast of 21.00 USD and a high forecast of 26.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.870
sliders
Low
21.00
Averages
23.33
High
26.00
Current: 6.870
sliders
Low
21.00
Averages
23.33
High
26.00
JonesResearch
Soumit Roy
Buy
initiated
$21
2025-05-22
Reason
JonesResearch
Soumit Roy
Price Target
$21
2025-05-22
initiated
Buy
Reason
Scotiabank
George Farmer
Buy
Initiates
$12
2025-04-16
Reason
Scotiabank
George Farmer
Price Target
$12
2025-04-16
Initiates
Buy
Reason
Cantor Fitzgerald
Li Watsek
Buy
Initiates
n/a
2025-03-14
Reason
Cantor Fitzgerald
Li Watsek
Price Target
n/a
2025-03-14
Initiates
Buy
Reason
Cantor Fitzgerald analyst Li Watsek initiated coverage of Protara Therapeutics with an Overweight rating.
HC Wainwright & Co.
Andrew Fein
Strong Buy
Reiterates
$23
2025-03-06
Reason
HC Wainwright & Co.
Andrew Fein
Price Target
$23
2025-03-06
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Andrew Fein
Strong Buy
Reiterates
$23
2024-12-06
Reason
HC Wainwright & Co.
Andrew Fein
Price Target
$23
2024-12-06
Reiterates
Strong Buy
Reason
Guggenheim
Michael Schmidt
Strong Buy
Reiterates
$20
2024-12-06
Reason
Guggenheim
Michael Schmidt
Price Target
$20
2024-12-06
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Protara Therapeutics Inc (TARA.O) is -4.83, compared to its 5-year average forward P/E of -1.78. For a more detailed relative valuation and DCF analysis to assess Protara Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.78
Current PE
-4.83
Overvalued PE
-0.41
Undervalued PE
-3.15

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.06
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.75
Undervalued EV/EBITDA
-0.63

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
6.59
Current PS
0.00
Overvalued PS
36.01
Undervalued PS
-22.84
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

TARA.O News & Events

Events Timeline

(ET)
2025-12-04
16:50:00
JPMorgan, TD Cowen and Piper Sandler Jointly Manage New Stock Offering
select
2025-12-04
16:20:00
Protara Therapeutics Launches $75M Public Offering
select
2025-12-03 (ET)
2025-12-03
08:10:00
Protara Updates TARA-002 Clinical Trial Data
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
11:22 AMGlobenewswire
Protara Prices 13.04M Shares at $5.75, Raising $75M for Clinical Development
  • Offering Size: Protara Therapeutics announced the pricing of 13,043,479 shares at $5.75 each, raising approximately $75 million, which will provide crucial funding for its clinical programs.
  • Additional Option: The underwriters have a 30-day option to purchase an additional 1,956,521 shares, which, if exercised, will further enhance the company's financing capacity to support its research in cancer and rare diseases.
  • Use of Proceeds: The net proceeds from this offering will be directed towards the clinical development of TARA-002 and other clinical programs, indicating the company's strong commitment to its R&D pipeline aimed at bringing innovative therapies to market.
  • Underwriting Team: J.P. Morgan, TD Cowen, and Piper Sandler are acting as joint book-running managers, reflecting market confidence in Protara and potentially enhancing its reputation among investors.
[object Object]
Preview
8.5
05:22 AMGlobenewswire
Protara Therapeutics Launches $75 Million Underwritten Public Offering
  • Fundraising Initiative: Protara Therapeutics has announced the commencement of a $75 million underwritten public offering aimed at raising capital through the issuance of common stock or pre-funded warrants to support the clinical development of therapies for cancer and rare diseases.
  • Underwriter Arrangement: The offering is being managed by J.P. Morgan, TD Cowen, and Piper Sandler, with an expected 30-day option for underwriters to purchase additional shares, which could enhance market liquidity and investor interest.
  • Use of Proceeds: Protara intends to allocate the net proceeds from the offering towards the clinical development of TARA-002 and other clinical programs, while also considering working capital and general corporate purposes, indicating a strategic focus on advancing its pipeline.
  • Market Risk Advisory: The offering is subject to market and other conditions, with Protara cautioning investors that the actual size and terms of the offering may vary, reflecting the inherent uncertainties in capital markets.
[object Object]
Preview
9.0
12-03Newsfilter
Protara's TARA-002 Shows 72% Complete Response Rate in NMIBC Patients
  • Clinical Trial Results: TARA-002 demonstrates a 72% complete response rate in BCG-Naïve NMIBC patients, indicating significant potential in treating non-muscle invasive bladder cancer, which could transform existing treatment paradigms.
  • Safety Profile: The trial reported no Grade 3 or higher treatment-related adverse events, showcasing TARA-002's favorable safety and tolerability, which will enhance confidence among physicians and patients regarding this therapy.
  • FDA Feedback: The company received written feedback from the FDA on the registrational path for TARA-002, confirming that BCG is not required as a comparator, providing flexibility for future trial designs and potentially accelerating the approval process.
  • Trial Progress: The company expects to report interim results from approximately 25 evaluable BCG-Unresponsive patients in Q1 2026 and aims to complete enrollment of this registrational cohort in the second half of 2026, demonstrating a proactive approach in advancing clinical development.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Protara Therapeutics Inc (TARA.O) stock price today?

The current price of TARA.O is 6.87 USD — it has increased 1.03 % in the last trading day.

arrow icon

What is Protara Therapeutics Inc (TARA.O)'s business?

Protara Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in advancing transformative therapies for people with cancer and rare diseases. The Company’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin (BCG), as well as a Phase II trial in pediatric patients with LMs. In addition, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes.

arrow icon

What is the price predicton of TARA.O Stock?

Wall Street analysts forecast TARA.O stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TARA.O is 23.33 USD with a low forecast of 21.00 USD and a high forecast of 26.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Protara Therapeutics Inc (TARA.O)'s revenue for the last quarter?

Protara Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Protara Therapeutics Inc (TARA.O)'s earnings per share (EPS) for the last quarter?

Protara Therapeutics Inc. EPS for the last quarter amounts to -0.31 USD, decreased -38.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Protara Therapeutics Inc (TARA.O)'s fundamentals?

The market is revising No Change the revenue expectations for Protara Therapeutics, Inc. (TARA) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 116.72%.
arrow icon

How many employees does Protara Therapeutics Inc (TARA.O). have?

Protara Therapeutics Inc (TARA.O) has 28 emplpoyees as of December 05 2025.

arrow icon

What is Protara Therapeutics Inc (TARA.O) market cap?

Today TARA.O has the market capitalization of 265.09M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free